A detailed history of Baillie Gifford & CO transactions in Exscientia PLC stock. As of the latest transaction made, Baillie Gifford & CO holds 3,848,276 shares of EXAI stock, worth $18.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,848,276
Previous 4,397,618 12.49%
Holding current value
$18.6 Million
Previous $22.4 Million 16.27%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$4.26 - $6.0 $2.34 Million - $3.3 Million
-549,342 Reduced 12.49%
3,848,276 $18.8 Million
Q2 2024

Jul 25, 2024

SELL
$3.99 - $6.04 $705,380 - $1.07 Million
-176,787 Reduced 3.86%
4,397,618 $22.4 Million
Q1 2024

May 01, 2024

SELL
$5.3 - $7.51 $615,197 - $871,723
-116,075 Reduced 2.47%
4,574,405 $26.2 Million
Q4 2023

Jan 26, 2024

SELL
$4.35 - $6.88 $775,735 - $1.23 Million
-178,330 Reduced 3.66%
4,690,480 $30.1 Million
Q3 2023

Nov 13, 2023

SELL
$4.52 - $8.9 $959,858 - $1.89 Million
-212,358 Reduced 4.18%
4,868,810 $22 Million
Q2 2023

Jul 28, 2023

SELL
$4.79 - $8.3 $770,768 - $1.34 Million
-160,912 Reduced 3.07%
5,081,168 $30.1 Million
Q1 2023

May 03, 2023

BUY
$5.3 - $10.93 $1.72 Million - $3.54 Million
323,785 Added 6.58%
5,242,080 $27.8 Million
Q4 2022

Jan 24, 2023

BUY
$4.1 - $8.94 $161,371 - $351,869
39,359 Added 0.81%
4,918,295 $26.2 Million
Q3 2022

Oct 27, 2022

BUY
$7.27 - $12.92 $50,126 - $89,083
6,895 Added 0.14%
4,878,936 $40.1 Million
Q2 2022

Aug 08, 2022

BUY
$6.92 - $15.97 $5.93 Million - $13.7 Million
856,706 Added 21.34%
4,872,041 $53.1 Million
Q1 2022

May 05, 2022

SELL
$11.52 - $22.05 $342,800 - $656,141
-29,757 Reduced 0.74%
4,015,335 $57.8 Million
Q4 2021

Jan 20, 2022

BUY
$17.63 - $27.1 $71.3 Million - $110 Million
4,045,092 New
4,045,092 $79.9 Million

Others Institutions Holding EXAI

About Exscientia plc


  • Ticker EXAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,461,000
  • Market Cap $593M
  • Description
  • Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on s...
More about EXAI
Track This Portfolio

Track Baillie Gifford & CO Portfolio

Follow Baillie Gifford & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.